Glenmark Acquires Leading OTC Brands From Wockhardt in the US for an Undisclosed Sum

Mumbai-based Glenmark Pharmaceuticals said it acquired the approved generic versions of some over-the-counter drugs from Wockhardt Ltd in the United States for an undisclosed sum. This decision should strengthen the acquirer’s OTC presence in the United States.

The acquisition by the Company’s wholly-owned subsidiary, Glenmark Pharmaceuticals Inc, USA, includes Approved Abbreviated New Drug Applications (ANDAs) for famotidine tablets, 10mg and 20mg, used to treat and prevent stomach and intestinal ulcers, the company said in a statement.

Glenmark did not disclose financial details. The stock ended at Rs 387, up 0.8% from BSE.

“The over-the-counter market has long been an important segment of Glenmark’s portfolio globally. Our acquisition of these ANDAs represents the continued expansion of our business in the OTC market here in the United States and our commitment to ensuring patients l ‘access to high-quality, affordable medicines,’ said President of Glenmark Pharmaceuticals Inc, USA, Sanjeev Krishan.

In the United States, Glenmark has acquired ANDAs of acid reflux medication cetirizine hydrochloride tablets, lansoprazole delayed-release capsules and olopatadine hydrochloride ophthalmic solution for allergic conjunctivitis and allergic rhinitis.

The company said its current portfolio consists of 175 products cleared for distribution in the US market and 48 ANDAs awaiting USFDA approval.

Dear reader,

Business Standard has always endeavored to provide up-to-date information and commentary on developments that matter to you and that have wider political and economic implications for the country and the world. Your constant encouragement and feedback on how to improve our offering has only strengthened our resolve and commitment to these ideals. Even in these challenging times stemming from Covid-19, we remain committed to keeping you informed and updated with credible news, authoritative opinions and incisive commentary on relevant topical issues.
However, we have a request.

As we battle the economic impact of the pandemic, we need your support even more so that we can continue to bring you more great content. Our subscription model has received an encouraging response from many of you who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of bringing you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practice the journalism we are committed to.

Support quality journalism and subscribe to Business Standard.

digital editor